Background/Aims: To evaluate the short-term outcome of the decision taken by the Hepatoma Board for the treatment of Hepatocellular carcinoma (HCC).
Materials and Methods: This was a prospective descriptive study involving 74 patients with HCC diagnosed by the
known criteria. The decisions taken by the Hepatoma Board for the 74 patients were as follows: 1- surgical resection
(7 patients), 2- local ablative therapy (LAT) (22 patients), 3- conventional transarterial chemoembolization (TACE)
(24 patients), and 4- palliative supportive care (21 patients).
Results: The short-term mortality rate was 25.7% of the total patients. The success rate was nearly equal in LAT
(68.2%) and surgery (71.4%), whereas the success rate was approximately 33.3% in TACE. There was no difference
in the mean total bilirubin level before and after LAT, surgery, or TACE (p>0.05 for each). There was a significant decrease in the mean serum albumin level after TACE (p=0.000). There was a decrease in the mean alpha fetoprotein
level after surgery and LAT (p=0.033) for surgery and (p=0.048) for LAT.
Conclusion: The management of HCC is better performed through a multidisciplinary team decision. Surgery has
comparable outcome to LAT but is more invasive. According to our local experience, conventional TACE has a success rate of 33.3%.